{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:05:25Z","timestamp":1789646725156,"version":"4.0.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02295-8","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:57:13Z","timestamp":1789646233000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["E7389-LF as a first-line chemotherapy for patients with metastatic\/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114"],"prefix":"10.1186","volume":"28","clinical-trial-number":[{"clinical-trial-number":"nct03207672","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hiroshi","family":"Ishiguro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yasojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Mukohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuto","family":"Naoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiko","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Otake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Semba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"3","key":"2295_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"2295_CR2","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andre F, Barrios CH, Cortes J, de Azambuja E, DeMichele A, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475\u201395.","journal-title":"Ann Oncol"},{"issue":"11","key":"2295_CR3","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1093\/jnci\/djac158","volume":"114","author":"L Gallicchio","year":"2022","unstructured":"Gallicchio L, Devasia TP, Tonorezos E, Mollica MA, Mariotto A. Estimation of the number of individuals living with metastatic cancer in the United States. J Natl Cancer Inst. 2022;114(11):1476\u201383.","journal-title":"J Natl Cancer Inst"},{"key":"2295_CR4","unstructured":"International Agency for Research on Cancer: Global Cancer Observatory. Available from: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations; RRID: SCR_012750. Accessed 6 Feb 2025."},{"issue":"12","key":"2295_CR5","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol. 2020;38(12):1346\u201366.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2295_CR6","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","volume":"142","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018;142(11):1364\u201382.","journal-title":"Arch Pathol Lab Med"},{"key":"2295_CR7","unstructured":"National Institute of Health: Cancer stat facts: Female breast cancer subtypes. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html. Accessed 12 Mar 2025."},{"issue":"1","key":"2295_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.hoc.2022.08.013","volume":"37","author":"E Nicolo","year":"2023","unstructured":"Nicolo E, Tarantino P, Curigliano G. Biology and treatment of HER2-low breast cancer. Hematol Oncol Clin North Am. 2023;37(1):117\u201332.","journal-title":"Hematol Oncol Clin North Am"},{"key":"2295_CR9","doi-asserted-by":"crossref","unstructured":"Orrantia-Borunda E, Anchondo-Nunez P, Acuna-Aguilar LE, Gomez-Valles FO, Ramirez-Valdespino CA: Subtypes of breast cancer. In: Mayrovitz HN editors. Breast cancer. Brisbane (AU); 2022.","DOI":"10.36255\/exon-publications-breast-cancer-subtypes"},{"issue":"4","key":"2295_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100087","volume":"36","author":"X Baez-Navarro","year":"2023","unstructured":"Baez-Navarro X, van Bockstal MR, Andrinopoulou ER, van Deurzen CHM. HER2-low breast cancer: incidence, clinicopathologic features, and survival outcomes from real-world data of a large nationwide cohort. Mod Pathol. 2023;36(4):100087.","journal-title":"Mod Pathol"},{"key":"2295_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.940239","volume":"12","author":"JI Lai","year":"2022","unstructured":"Lai JI, Chao TC, Liu CY, Huang CC, Tseng LM. A systemic review of taxanes and their side effects in metastatic breast cancer. Front Oncol. 2022;12:940239.","journal-title":"Front Oncol"},{"issue":"26","key":"2295_CR12","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666\u201376.","journal-title":"N Engl J Med"},{"issue":"4","key":"2295_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/jnci\/djz211","volume":"112","author":"SP Hey","year":"2020","unstructured":"Hey SP, Gyawali B, D\u2019Andrea E, Kanagaraj M, Franklin JM, Kesselheim AS. A systematic review and meta-analysis of bevacizumab in first-line metastatic breast cancer: lessons for research and regulatory enterprises. J Natl Cancer Inst. 2020;112(4):335\u201342.","journal-title":"J Natl Cancer Inst"},{"key":"2295_CR14","unstructured":"Pazdur R: Regulatory decision to withdraw Avastin (bevacizumab) first-line metastatic breast cancer indication. Rockville, MD: FDA Center for Drug Evaluation and Research; 2010. Available from: https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM237171.pdf. Accessed 6 Feb 2025."},{"issue":"22","key":"2295_CR15","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O\u2019Shaughnessy JA, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391(22):2110\u201322.","journal-title":"N Engl J Med"},{"issue":"1","key":"2295_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"key":"2295_CR17","unstructured":"Eisai Co., Ltd.: Halaven (eribulin mesylate) [prescribing information]; 2022, Tokyo, Japan."},{"issue":"6","key":"2295_CR18","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/bjc.2014.80","volume":"110","author":"T Yoshida","year":"2014","unstructured":"Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer. 2014;110(6):1497\u2013505.","journal-title":"Br J Cancer"},{"issue":"9769","key":"2295_CR19","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914\u201323.","journal-title":"Lancet"},{"issue":"6","key":"2295_CR20","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594\u2013601.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2295_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","volume":"148","author":"C Twelves","year":"2014","unstructured":"Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat. 2014;148(3):553\u201361.","journal-title":"Breast Cancer Res Treat"},{"key":"2295_CR22","doi-asserted-by":"crossref","unstructured":"Asano M, Hyodo K, Schuck E, Matsuji J, Ishihara H, Kikuchi H, Nomoto K. Characterization of the liposomal formulation of eribulin mesylate (E7389) in mice. Poster presented at AACR annual meeting; April 11\u201322, 2015; Philadelphia\/USA. Abstract #4543.","DOI":"10.1158\/1538-7445.AM2015-4543"},{"issue":"4","key":"2295_CR23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41416-019-0377-x","volume":"120","author":"TRJ Evans","year":"2019","unstructured":"Evans TRJ, Dean E, Molife LR, Lopez J, Ranson M, El-Khouly F, et al. Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours. Br J Cancer. 2019;120(4):379\u201386.","journal-title":"Br J Cancer"},{"issue":"9","key":"2295_CR24","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/1078-0432.CCR-21-3518","volume":"28","author":"J Sato","year":"2022","unstructured":"Sato J, Shimizu T, Koyama T, Iwasa S, Shimomura A, Kondo S, et al. Dose escalation data from the phase 1 study of the liposomal formulation of eribulin (E7389-LF) in Japanese patients with advanced solid tumors. Clin Cancer Res. 2022;28(9):1783\u201391.","journal-title":"Clin Cancer Res"},{"key":"2295_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2022.03.004","volume":"168","author":"N Masuda","year":"2022","unstructured":"Masuda N, Ono M, Mukohara T, Yasojima H, Shimoi T, Kobayashi K, et al. Phase 1 study of the liposomal formulation of eribulin (E7389-LF): results from the breast cancer expansion cohort. Eur J Cancer. 2022;168:108\u201318.","journal-title":"Eur J Cancer"},{"issue":"8","key":"2295_CR26","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1158\/1078-0432.CCR-22-3027","volume":"29","author":"K Shitara","year":"2023","unstructured":"Shitara K, Hirao M, Iwasa S, Oshima T, Komatsu Y, Kawazoe A, et al. Phase I study of the liposomal formulation of eribulin (E7389-LF): results from the advanced gastric cancer expansion cohort. Clin Cancer Res. 2023;29(8):1460\u20137.","journal-title":"Clin Cancer Res"},{"key":"2295_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4137\/BCBCR.S39615","volume":"10","author":"C Twelves","year":"2016","unstructured":"Twelves C, Awada A, Cortes J, Yelle L, Velikova G, Olivo MS, et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer (Auckl). 2016;10:77\u201384.","journal-title":"Breast Cancer (Auckl)"},{"issue":"4","key":"2295_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101592","volume":"8","author":"C Molinelli","year":"2023","unstructured":"Molinelli C, Jacobs F, Agostinetto E, Nader-Marta G, Ceppi M, Bruzzone M, et al. Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis. ESMO Open. 2023;8(4):101592.","journal-title":"ESMO Open"},{"issue":"4","key":"2295_CR29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1158\/1535-7163.MCT-22-0475","volume":"22","author":"Y Niwa","year":"2023","unstructured":"Niwa Y, Adachi K, Tabata K, Ishida R, Hotta K, Ishida T, et al. Liposome-encapsulated eribulin shows enhanced antitumor activity over eribulin for combination therapy with anti-PD-1 antibody. Mol Cancer Ther. 2023;22(4):499\u2013510.","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"2295_CR30","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","volume":"393","author":"J Cortes","year":"2025","unstructured":"Cortes J, Punie K, Barrios C, Hurvitz SA, Schneeweiss A, Sohn J, et al. Sacituzumab govitecan in untreated, advanced triple-negative breast cancer. N Engl J Med. 2025;393(19):1912\u201325.","journal-title":"N Engl J Med"},{"key":"2295_CR31","doi-asserted-by":"crossref","unstructured":"Dent RA, Schmid P, Cortes J, Cescon DW, Saji S, Jung KH, Bachelot T, Wang S, Basaran G, Chae YS et al: First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial. Poster presented at ESMO Congress; October 17\u201321, 2025; Berlin, Germany. Abstract #LBA21.","DOI":"10.1016\/j.annonc.2025.09.031"},{"key":"2295_CR32","unstructured":"United States Food and Drug Administration: FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer. 6 February 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-hr-positive-her2-low-or-her2. Accessed 31 Mar 2026."}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02295-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:57:21Z","timestamp":1789646241000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02295-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2295"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02295-8","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Study 114 was conducted in accordance with the Principles of the World Medical Association Declaration of Helsinki, all applicable Japanese Good Clinical Practices and regulations, and the Pharmaceutical and Medical Device Act for studies conducted in Japan. Prior to enrollment, patients signed informed consent forms. Ethical approval and written informed consent were granted and approved by the applicable local institutional review board.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H. Ishiguro reports receiving research funding and funding for participating in a speaker\u2019s bureau from Eisai, and served as a principal investigator for Eisai. Y. Miyoshi reports receiving research funding and honoraria from AstraZeneca, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Kyowa-Kirin, MSD, Pfizer, and Taiho, and consulting fees from Daiichi-Sankyo. H. Yasojima has no conflicts of interest to disclose. J. Watanabe reports receiving research funding and funding for serving as an invited speaker and on an advisory board from Eisai. T. Takano reports receiving funding for serving as an invited speaker from Chugai, Daiichi-Sankyo, and Eli Lilly, for serving on an advisory board from Daiichi-Sankyo, Eisai, and Gilead, and for serving as a principal investigator from AstraZeneca, Chugai, Daiichi-Sankyo, Eli Lilly, Eisai, Gilead, and MSD. A. Shimomura reports receiving research funding from Eisai. E. Tokunaga reports receiving research funding and funding for serving on a speaker\u2019s bureau from Eisai, and has served as a principal investigator for Eisai. T. Mukohara reports receiving research funding from Eisai, Daiichi-Sankyo, Sysmex, MSD, Pfizer, Sanofi, and Chugai Pharmaceuticals. Y. Naoi reports receiving research funding and funding for serving as a speaker from Eisai. D. Matsuoka, S. Okumura, Y. Otake, T. Suzuki, T. Takase, T. Semba, and Z. Zhao are employees of Eisai Co., Ltd. K. Yonemori reports receiving research funding from AstraZeneca, Boehringer Ingelheim, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Genmab, Haihe, Kyowa Hakko Kirin, Merck Sharp & Dohme LLC, Nihon Kayaku, Novartis, Ono, Pfizer, Sanofi, Seattle Genetics, Taiho, and Takeda, consulting fees from AstraZeneca, Chugai, Eisai, Genmab, Novartis, OncXerna, Sanofi, and Takeda, and lectures fees from Pfizer, Eisai, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi-Sankyo, Eli Lilly, FujiFilm Pharma, MSD, Ono, PDR Pharma, Sanofi, and Takeda.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"158"}}